Table 1

Patient characteristics

No of patients, male/female, n23/5
Median age at study entry, years (range)38.5 (24–62)
Median onset of disease, years (range)27 (8–57)
Median duration of disease, years (range)10.4 (2–29)
HLA B27 positive/negative/unknown not determined, n17/7/4
Time intervals of infliximab infusions before MRI assessment, median, weeks (range)6 (4–12)
Median dose of infliximab, mg/kg body weight (range)4.45 (3–6)
Regular NSAID intake, n1
Concomitant DMARD therapy, n15
  • DMARD, disease-modifying antirheumatic drug; MRI, magnetic resonance imaging; NSAID, non-steroidal anti-inflammatory drug.